GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population

Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in ...

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by VivaniALAMEDA, Calif., July ...

Cyllene Therapeutics Raises €33 Million Series C

Cyllene Therapeutics ("Cyllene"), formerly known as EG 427, today announced the closing of a €33 million Series C financing round co-led by GordonMD Global Investments® LP ("GordonMD") and Merck ...